Japan's PMDA warns of serious AEs with pivoxil use in kids

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2012年 / 1407卷 / 1期
关键词：
Public Health; Adverse Event; Otitis Medium; Carnitine; Medical Device;
D O I：
10.2165/00128415-201214070-00003
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2 / 2
相关论文
共 50 条
  • [41] FDA warns of serious hematologic reactions with off-label use of quinine sulfate for night-time leg cramps
    不详
    FORMULARY, 2010, 45 (08) : 264 - 264
  • [42] Coroner warns about use of physician associates in the NHS after woman's death
    Hubbard, Ella
    BMJ-BRITISH MEDICAL JOURNAL, 2025, 388
  • [43] Does the yen have a future? - Japan's economy needs serious reforms
    Preisinger-Monloup, M
    INTERNATIONALE POLITIK, 2003, 58 (02): : 29 - 34
  • [44] The use of clay in Japan's contemporary architecture
    Cuddon, K
    CERAMICS-TECHNICAL, 2005, (21) : 7 - 10
  • [45] PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs: approval of nivolumab for unresectable advanced or recurrent epithelial skin malignancies in Japan
    Matsumura, Noriomi
    Mandai, Masaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (06) : 639 - 639
  • [46] Recently approved indications for human growth hormone pharmaceuticals in Japan: Review of applications for use in small for gestational age and adult gh deficiency patients at PMDA
    Hirano, Mai
    Makie, Toshio
    Sano, Yukie
    Matsuda, Fumiko
    Ishida, Mari
    Shinohara, Kayo
    Asano, Junichi
    Ogawa, Michihiro
    Kato, Naoto
    Hosoki, Rumiko
    Yamada, Masanobu
    Hirata, Masakazu
    ENDOCRINE JOURNAL, 2010, 57 : S520 - S521
  • [47] Potential factors correlating to the PMDA’s decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan
    Keitaro Nakajima
    Koji Chiba
    Hisao Tsubamoto
    Jaimie Walsh
    Laurie Strawn
    Toshio Suwa
    Investigational New Drugs, 2013, 31 : 1051 - 1055
  • [48] THE USE OF PATIENT REPORTED OUTCOMES (PROS) BY THE PHARMACEUTICAL INDUSTRY IN JAPAN - A BRIEF REVIEW OF PMDA DATA IN COMPARISON WITH FDA AND EMA-APROVED LABEL CLAIMS
    Ledesma, D. A.
    Tanaka, E.
    Adachi, K.
    Rossi, B.
    VALUE IN HEALTH, 2014, 17 (07) : A517 - A517
  • [49] Potential factors correlating to the PMDA's decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan
    Nakajima, Keitaro
    Chiba, Koji
    Tsubamoto, Hisao
    Walsh, Jaimie
    Strawn, Laurie
    Suwa, Toshio
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) : 1051 - 1055
  • [50] Kids in the City: Children's Use and Experiences of Urban Neighbourhoods in Auckland, New Zealand
    Carroll, Penelope
    Witten, Karen
    Kearns, Robin
    Donovan, Phil
    JOURNAL OF URBAN DESIGN, 2015, 20 (04) : 417 - 436
12345